Medicine and Dentistry
Neoadjuvant Chemotherapy
75%
Cystectomy
68%
Specimen
25%
Muscle Invasive Bladder Cancer
25%
Inpatient
25%
Transurethral Resection
18%
Surveillance
12%
Overall Survival
12%
Biological Marker
12%
Urine
12%
Blood
12%
Tissues
12%
Morbidity
6%
Carcinoma
6%
Lesion
6%
Combination Therapy
6%
Surgical Technique
6%
RNA
6%
Patient Experience
6%
X-Ray Computed Tomography
6%
Cisplatin
6%
Diagnosis
6%
Positron Emission Tomography-Computed Tomography
6%
Scar Tissue
6%
Cytotechnology
6%
Minimal Residual Disease
6%
Fluorodeoxyglucose F 18
6%
Cystoscopy
6%
Absence
6%
Urothelial Cancer
6%
Association
6%
Examination
6%
Therapeutic Procedure
6%
Analysis
6%
Nursing and Health Professions
Patient
100%
Cystectomy
68%
Overall Survival
12%
Biological Marker
12%
Staging
12%
Prospective Cohort Study
6%
Morbidity
6%
Combination Therapy
6%
Carcinoma
6%
Biopsy
6%
Diagnosis
6%
Positron Emission Tomography-Computed Tomography
6%
Surgical Technique
6%
DNA
6%
X-Ray Computed Tomography
6%
Fluorodeoxyglucose F 18
6%
RNA
6%
Minimal Residual Disease
6%
Procedures
6%
Analysis
6%
Examination
6%
Cisplatin
6%
Prediction
6%
Absence
6%
Cytology
6%
Pharmacology, Toxicology and Pharmaceutical Science
Muscle Invasive Bladder Cancer
25%
Overall Survival
12%
Biological Marker
12%
Randomized Controlled Trial
12%
Carcinoma
6%
RNA
6%
Cisplatin
6%
Morbidity
6%
Minimal Residual Disease
6%
DNA
6%
Fluorodeoxyglucose F 18
6%
Absence
6%
Neuroscience
Chemotherapy
75%
Randomized Controlled Trial
6%
DNA
6%
Cisplatin
6%
RNA
6%
Biochemistry, Genetics and Molecular Biology
Staging
12%
Overall Survival
12%
X-Ray Computed Tomography
6%
Morbidity
6%
Positron Emission Tomography-Computed Tomography
6%
Cisplatin
6%
Prospective Cohort Study
6%
Association
6%
Experience
6%